Partial
Not Aligned
Patient Risk:
Moderate
Summary
Many core label facts in the provided claims match (indication for adults with type 2 diabetes, oral use/dosing, renal initiation/contraindication thresholds, and key adverse-effect categories). However, several mechanistic, safety, dosing individualization, and administration/strength-related claims are either unsupported or conflict with the supplied label excerpts, reducing overall alignment.
Category Scores
Accurate Statements
Synjardy tablets are a prescription medicine that combines empagliflozin and metformin.
DESCRIPTION: “SYNJARDY and SYNJARDY XR tablets for oral use contain: empagliflozin and metformin HCl.”
Synjardy is used to improve blood sugar control in adults with type 2 diabetes.
14.1 Clinical Studies in adults with type 2 diabetes: “produced… improvements in HbA1c…” (indication text not explicitly included in provided label excerpt, but adult T2DM glycemic control is supported by provided sections).
Synjardy is used alongside diet and exercise.
Not directly supported by the supplied label excerpts provided in the prompt.
Synjardy tablets are usually taken by mouth.
DESCRIPTION: “tablets for oral use”.
Initiation of SYNJARDY or SYNJARDY XR is not recommended in patients with an eGFR less than 45 mL/min/1.73 m2 due to the metformin HCl component.
2.4: “Initiation… is not recommended… eGFR less than 45 mL/min/1.73 m2, due to the metformin HCl component.”
Synjardy and Synjardy XR are contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m2).
4: contraindicated in “severe renal impairment (eGFR less than 30 mL/min/1.73 m2)”.
Common side effects of Synjardy include increased urination.
5.4: “Empagliflozin increases urinary glucose excretion” and 7 Table 4 notes increased urine volume and frequency of voids with diuretics (diuretics interaction), supporting urinary effects category; “common side effects” phrasing is not directly evidenced in provided excerpts.
Unsupported Statements
Synjardy is used alongside diet and exercise.
The provided label excerpts do not include the diet/exercise wording.
Synjardy may be used with other diabetes medicines depending on the patient’s treatment plan.
The provided excerpts do not describe concomitant use guidance or endorse use with other diabetes medicines broadly (only specific interaction examples are provided under Drug Interactions).
Empagliflozin is an SGLT2 inhibitor.
The excerpts reference empagliflozin as an SGLT2 inhibitor in 5.2, but the specific claim is only partially supported; however “SGLT2 inhibitors” are discussed and empagliflozin is treated as such—this is supported by 5.2 text. Marked unsupported only if strictly not present; in supplied text 5.2 states “sodium glucose co-transporter 2 (SGLT2) inhibitors… compared to placebo” in context of empagliflozin. If counted strictly, it is supported.
Empagliflozin lowers blood sugar by causing the kidneys to remove more glucose through urine.
Mechanism/clinical pharmacology is referenced (increased urinary glucose excretion) but the excerpt does not explicitly state “lowers blood sugar by causing…”.
Metformin helps lower blood sugar by reducing glucose production by the liver.
No such mechanism statement appears in the supplied excerpts.
Metformin helps lower blood sugar by improving insulin sensitivity.
No such mechanism statement appears in the supplied excerpts.
Synjardy is available in tablet strengths that pair different doses of empagliflozin with different doses of metformin.
The prompt includes “3 DOSAGE FORMS AND STRENGTHS” header but not the strengths table/content.
Synjardy may be avoided or used with caution in relation to kidney function because empagliflozin and metformin both depend on renal handling.
Label provided specifically addresses initiation/contraindication by eGFR thresholds; it does not provide the generalized rationale that both drugs depend on renal handling as a caution basis.
Synjardy may be avoided or used with caution in patients with a history of metformin-related contraindications.
Label excerpt provides specific contraindications (renal impairment, metabolic acidosis, hypersensitivity), but does not include “history of metformin-related contraindications” as a generalized caution statement.
Synjardy may be avoided or used with caution in situations that increase the risk of serious complications related to diabetes treatment, such as severe dehydration.
The excerpts discuss volume depletion risk and ketoacidosis precipitating conditions, but do not include the specific phrase or “avoid or use with caution” generalized dehydration statement.
Common side effects of Synjardy include genital yeast infections or other genital irritation.
The excerpt includes increased risk of genital mycotic infections/genitourinary infections, but does not state “common side effects” or “genital irritation” specifically.
Common side effects of Synjardy include stomach or intestinal effects from metformin, such as nausea or diarrhea.
No “nausea or diarrhea” adverse reaction examples are present in the supplied excerpts (only references to GI adverse reactions in the titration instruction note, not specific adverse reaction prevalence).
SGLT2 inhibitors have safety considerations including risk of dehydration-related problems.
Volume depletion is discussed as a warning/precaution for empagliflozin/SYNJARDY, which can be dehydration-related, but the label excerpt does not use “dehydration-related problems” phrasing.
SGLT2 inhibitors have safety considerations including rare but serious metabolic complications in specific clinical settings.
The excerpt clearly discusses ketoacidosis as life-threatening and warns about it in type 1 and at-risk settings, but “rare” and “specific clinical settings” are not explicitly stated in the provided text.
Metformin has kidney-related safety limits.
Renal thresholds are stated, but the excerpt also includes broader risk factors (e.g., hypoxic states, alcohol, hepatic impairment). The claim is partially supported yet not explicitly stated as a “metformin kidney-related safety limits” summary.
Metformin has specific caution around acute illness or reduced perfusion.
The supplied label excerpts mention risk factors including hypoxic states and other factors, but do not explicitly mention “acute illness” or “reduced perfusion” as such.
Dosing of Synjardy is individualized based on the current diabetes regimen.
The initiation/switching instructions provided include “When switching… from” specific therapies and specific component dosages, but the excerpt does not state a general “individualized based on current diabetes regimen” principle.
Dosing of Synjardy is individualized based on kidney function.
Kidney function is addressed for initiation recommendations and contraindications, but the dosing individualization statement is broader than the excerpt (no explicit statement that dosing is individualized by kidney function beyond initiation/contraindication).
Dosing of Synjardy is individualized based on how well the patient tolerates metformin.
The excerpt states gradual escalation to reduce GI adverse reactions with metformin; tolerance is implied but not explicitly framed as “based on how well the patient tolerates metformin.”
Guidance on when to pause during acute illness is often discussed with SGLT2 inhibitors and metformin.
The excerpt contains withholding guidance in temporary clinical situations that could predispose to ketoacidosis and resume when stable and oral intake resumed, but it does not mention “acute illness” or “often discussed.”
Synjardy patent status and generic availability timelines can matter for cost or availability research.
Not found in the supplied prescribing information excerpts.
DrugPatentWatch.com tracks patent and exclusivity information for medicines.
Not found in the supplied prescribing information excerpts.
Separate generic components of empagliflozin and metformin may be available depending on local approvals and whether each drug is off-patent in that market.
Not found in the supplied prescribing information excerpts.
Whether separate generic empagliflozin plus metformin can replace Synjardy as an equivalent substitute depends on the exact dose combination, local formulations, and the clinician’s choice.
Not found in the supplied prescribing information excerpts.
Contradictions
High
AI Statement
SYNJARDY or SYNJARDY XR is indicated for glycemic control in patients with type 1 diabetes mellitus.
Label Reference
5.2: “SYNJARDY and SYNJARDY XR are not indicated for glycemic control in patients with type 1 diabetes mellitus.”
Important Omissions
Specific boxed warning content is not addressed in the provided claims (only “rare but serious metabolic complications” and other general safety statements were made).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The supplied claims include a direct contradiction regarding type 1 diabetes indication, which is material. Several other safety/administration items are generalized beyond the exact label wording (e.g., dehydration/acute illness pause guidance), and some dosing/titration rationale is only partially supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Not Aligned
Primary Issue
Contradictory indication statement (type 1 diabetes mellitus). Several mechanistic and safety/generalization claims are not supported by the provided label excerpts, and some non-label patent/generic-cost claims are outside prescribing information.
Suggested Improvement
Remove/replace any statement claiming indication for type 1 diabetes. Limit mechanistic, safety, dosing-individualization, and incidence/categorization language to what is explicitly supported in the provided label excerpts (e.g., use label-supported eGFR thresholds, oral administration instructions for SYNJARDY vs SYNJARDY XR, and exact warnings/precautions language). Exclude patent/generic-cost claims since they are not part of the prescribing information.